Table 5.
Associations Between Rate of Quantitative Interstitial Abnormality Progression and Rates of Change in Clinical Outcomes Stratified by GOLD Groups
| Group | FVC (mL/y) |
6-Min Walk Distance (m/y) |
Mortality (Hazard Ratio) |
|||
|---|---|---|---|---|---|---|
| Effect,a Mean (95% CI) | P Value | Effect,a Mean (95% CI) | P Value | Effect,a Mean (95% CI) | P Value | |
| PRISm (n = 563) | –13.2 (–20.8 to –5.5) | < .001 | 0.2 (–2.3 to 2.6) | .90 | 1.39 (0.69 to 2.82) | .36 |
| GOLD stage 0 (n = 2,122) | –9.9 (–14.5 to –5.2) | < .001 | –1.2 (–2.7 to 0.3) | .11 | 1.54 (1.00 to 2.38) | .049 |
| GOLD stages 1-4 (n = 1,874) | –6.4 (–14.5 to 1.7) | .12 | –2.1 (–3.9 to –0.3) | .02 | 1.87 (1.41 to 2.47) | < .001 |
Adjusted for age; sex; self-reported race; baseline: quantitative interstitial abnormalities, emphysema, airway wall thickness (COPDGene only), smoking status, pack-years, and BMI; and change in: emphysema, smoking status (COPDGene only), BMI, and scanner manufacturer. GOLD = Global Initiative for Chronic Obstructive Lung Disease; PRISm = preserved ratio impaired spirometry.
a
Effect expressed as the association between the annual rate of change (percent per year) in quantitative interstitial abnormalities and rate of change in the clinical outcome or the hazard ratio for all-cause mortality.